MTOR inhibitors in renal cell carcinoma

Therapy

Volumn 8, Issue 4, 2011, Pages 359-367

  Battelli, Chiara ^a   Cho, Daniel C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Akt; everolimus; mTOR; PI3 K; rapamycin; renal cancer; renal cell carcinoma; temsirolimus; TORC1

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; FK 506 BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ANEMIA; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; PATIENT SELECTION; PERIPHERAL EDEMA; PNEUMONIA; RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS;

EID: 79961060638     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.32     Document Type: Review

References (38)

1. Guertin DA, Sabatini DM. The pharmacology of mTOR Inhibition. Sci. Signal. 2(67), PE24 (2009).
2. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124(3), 471-484 (2006).
3. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 25(4), 209-226 (2007).
4. Holland EC, Sonenberg N, Pandolfi PP, Thomas G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23(18), 3138-3144 (2004). (Pubitemid 38638825)
5. Konicek BW, Dumstorf CA, Graff JR. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 7(16), 2466-2471 (2008).
6. Dowling RJ, Topisirovic I, Alain T et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328(5982), 1172-1176 (2010).
7. Fredrickson RM, Mushynski WE, Sonenberg N. Phosphorylation of translation initiation factor eIF-4E is induced in a ras-dependent manner during nerve growth factor-mediated PC12 cell differentiation. Mol. Cell. Biol. 12(3), 1239-1247 (1992).
8. Toschi A, Edelstein J, Rockwell P, Ohh M, Foster DA. HIFa expression in VHL-deficient renal cancer cells is dependent on phospholipase D. Oncogene 27(19), 2746-2753 (2008). (Pubitemid 351581463)
9. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12(1), 122-127 (2006). (Pubitemid 43050086)
10. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mMTORC2 assembly and Akt/PKB. Mol. Cell 22(2), 159-168 (2006).
11. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol. Cell. Biol. 29(6), 1411-1420 (2009).
12. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl Acad. Sci. USA 105(45), 17414-17419 (2008).
13. Araki K, Turner AP, Shaffer VO et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460(7251), 108-112 (2009).
14. Alexander AA, Maniar A, Cummings JS et al.: Isopentenyl pyrophosphate-activated CD56+ {g}{d} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin. Cancer Res. 14(13), 4232-4240 (2008).
15. Li H, Pauza CD. Rapamycin increases the yield and effector function of human gd T cells stimulated in vitro. Cancer Immunol. Immunother. 60(3), 361-370 (2011).
16. Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br. J. Cancer 104(4), 643-652 (2011).
17. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007). (Pubitemid 46849157)
18. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004). (Pubitemid 41103603)
19. Motzer RJ, Escudier B, Oudard S et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
20. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18), 4256-4265 (2010).
21. Merchan JR, Pitot HC, Qin R et al. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients. Presented at: 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando, FL, USA, 29 May-2 June 2009.
22. Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol. 28(13), 2131-2136 (2010).
23. Knox JJ, Kay AC, Schiff E et al. First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC). Presented at: 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, USA, 4-8 June 2010.
24. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-a on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 26(2), 202-209 (2009).
25. Sun SY, Rosenberg LM, Wang X et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65(16), 7052-7058 (2005). (Pubitemid 41161231)
26. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005). (Pubitemid 40262113)
27. Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3-K-dependent feedback loop in human cancer. J. Clin. Invest. 118(9), 3065-3074 (2008).
28. Zhao H, Ehara H, Akao Y et al. Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem. Biophys. Res. Commun. 278(1), 140-143 (2000).
29. Kondo K, Kim WY, Lechpammer M, Kaelin WG. Inhibition of HIF2a is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1(3), 439-444 (2003).
30. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 a and 2 a on mTORC1 and mMTORC2. J. Biol. Chem. 283(50), 34495-34499 (2008).
31. Gordan JD, Lal P, Dondeti VR et al. HIF-a effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6), 435-446 (2008).
32. Shi Y, Gera J, Hu L et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62(17), 5027-5034 (2002). (Pubitemid 34984430)
33. Cho D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 5(6), 379-385 (2007). (Pubitemid 47584475)
34. Cejka D, Kuntner C, Preusser M et al. FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. Br. J. Cancer 100, 1739-1745 (2009).
35. Cho DC, Cohen MB, Panka DJ et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 16(14), 3628-3638 (2010).
36. Serra V, Markman B, Scaltriti M et al. NVP-BEZ235, a dual PI3-K/mTOR inhibitor, prevents PI3-K signaling and inhibits the growth of cancer cells with activating PI3-K mutations. Cancer Res. 68(19), 8022-8030 (2008).
37. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway. The second generation of inhibitors. Mol. Cancer Ther. 10(3), 395-403 (2011).
38. Cho DC, Atkins MB. Everolimus: emerging evidence of its therapeutic impact in patients with advanced renal cell carcinoma. Clin. Med. Rev. Oncol. (2010) (In press).